Announcements Trials
Browse Landscape

Phase

Phase 4 1Phase 2 1

Status

Withdrawn 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Head & Neck 1

Conditions

Lymphoma, Follicular 1Head and Neck Neoplasms 1Depressive Disorder, Major 1Depressive Disorder 1Bipolar Disorder 1

Interventions

Cisplatin 4Morphine 3Fluorouracil 3Fentanyl 3Norepinephrine 2Gabapentin 2Docetaxel 2Cetuximab 2technetium-diethylenetriaminepentaacetic acid-mannosyl-dextran 1technetium Tc 99m nanocolloid 1nimotuzumab 1dopexamine 1apixaban 1Venlafaxine Hydrochloride 1Tobacco Use Cessation Devices 1Taste 1Sugars 1Saline Solution 1Radiotherapy, Intensity-Modulated 1Radiosurgery 1Psychiatric Rehabilitation 1Pregabalin 1Polymerase Chain Reaction 1Patient-Specific Modeling 1Oxycodone 1Oral Hygiene 1Neck Dissection 1Mitomycin 1Mirtazapine 1Methadone 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 4 × Head and Neck Neoplasms × Venlafaxine Hydrochloride × Clear all
NCT04977271 2025-02-04

Mood Disorders in Head and Neck Cancer Patients

University of Alabama at Birmingham

Phase 4 Withdrawn
Head & Neck

Depressive Disorder, Head and Neck Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡